Rocket Pharmaceuticals to Participate in the Bank of America Securities 2023 Healthcare Conference
03 Maio 2023 - 5:01PM
Business Wire
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading
late-stage biotechnology company advancing an integrated and
sustainable pipeline of genetic therapies for rare disorders with
high unmet need, today announced that Gaurav Shah, M.D., Chief
Executive Officer, is scheduled to participate in a fireside chat
at the Bank of America Securities 2023 Healthcare Conference in Las
Vegas, Nevada on Wednesday, May 10, 2023 at 4:20 p.m. PT.
A live audio webcast of the presentation will be available under
“Events” in the Investors section of the Company’s website at
https://ir.rocketpharma.com/. A webcast replay will be available on
the Rocket website following the conference.
About Rocket Pharmaceuticals, Inc. Rocket
Pharmaceuticals, Inc. (NASDAQ: RCKT) is advancing an integrated and
sustainable pipeline of investigational genetic therapies designed
to correct the root cause of complex and rare disorders. The
Company’s platform-agnostic approach enables it to design the best
therapy for each indication, creating potentially transformative
options for patients afflicted with rare genetic diseases. Rocket's
clinical programs using lentiviral vector (LV) based gene therapy
are for the treatment of Fanconi Anemia (FA), a difficult to treat
genetic disease that leads to bone marrow failure and potentially
cancer, Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric
genetic disorder that causes recurrent and life-threatening
infections which are frequently fatal, and Pyruvate Kinase
Deficiency (PKD), a rare, monogenic red blood cell disorder
resulting in increased red cell destruction and mild to
life-threatening anemia. Rocket’s first clinical program using
adeno-associated virus (AAV)-based gene therapy is for Danon
Disease, a devastating, pediatric heart failure condition. Rocket
also has preclinical AAV-based gene therapy programs in
PKP2-arrhythmogenic cardiomyopathy (ACM) and BAG3-associated
dilated cardiomyopathy (DCM). For more information about Rocket,
please visit www.rocketpharma.com.
Rocket Cautionary Statement Regarding Forward-Looking
Statements Various statements in this release concerning
Rocket’s future expectations, plans and prospects, including
without limitation, Rocket’s expectations regarding the safety and
effectiveness of product candidates that Rocket is developing to
treat Fanconi Anemia (FA), Leukocyte Adhesion Deficiency-I (LAD-I),
Pyruvate Kinase Deficiency (PKD), Danon Disease (DD) and other
diseases, the expected timing and data readouts of Rocket’s ongoing
and planned clinical trials, the expected timing and outcome of
Rocket’s regulatory interactions and planned submissions, Rocket’s
plans for the advancement of its Danon Disease program, including
its planned pivotal trial, and the safety, effectiveness and timing
of related pre-clinical studies and clinical trials, may constitute
forward-looking statements for the purposes of the safe harbor
provisions under the Private Securities Litigation Reform Act of
1995 and other federal securities laws and are subject to
substantial risks, uncertainties and assumptions. You should not
place reliance on these forward-looking statements, which often
include words such as “aim,” “anticipate,” "believe," “can,”
“continue,” “design,” “estimate,” "expect," "intend," “may,”
"plan," “potential,” "will give," "seek," "will," "may," "suggest"
or similar terms, variations of such terms or the negative of those
terms. Although Rocket believes that the expectations reflected in
the forward-looking statements are reasonable, Rocket cannot
guarantee such outcomes. Actual results may differ materially from
those indicated by these forward-looking statements as a result of
various important factors, including, without limitation, Rocket’s
ability to monitor the impact of COVID-19 on its business
operations and take steps to ensure the safety of patients,
families and employees, the interest from patients and families for
participation in each of Rocket’s ongoing trials, patient
enrollment, trial timelines and data readouts, our expectations
regarding our drug supply for our ongoing and anticipated trials,
actions of regulatory agencies, which may affect the initiation,
timing and progress of pre-clinical studies and clinical trials of
its product candidates, our ability to submit regulatory filings
with the U.S. Food and Drug Administration (FDA) and to obtain and
maintain FDA or other regulatory authority approval of our product
candidates, Rocket’s dependence on third parties for development,
manufacture, marketing, sales and distribution of product
candidates, the outcome of litigation, our competitors’ activities,
including decisions as to the timing of competing product launches,
pricing and discounting, our integration of an acquired business,
which involves a number of risks, including the possibility that
the integration process could result in the loss of key employees,
the disruption of our ongoing business, or inconsistencies in
standards, controls, procedures, or policies, our ability to
successfully develop and commercialize any technology that we may
in-license or products we may acquire and any unexpected
expenditures, as well as those risks more fully discussed in the
section entitled "Risk Factors" in Rocket’s Annual Report on Form
10-K for the year ended December 31, 2022, filed February 28, 2023
with the SEC and subsequent filings with the SEC including our
Quarterly Reports on Form 10-Q. Accordingly, you should not place
undue reliance on these forward-looking statements. All such
statements speak only as of the date made, and Rocket undertakes no
obligation to update or revise publicly any forward-looking
statements, whether as a result of new information, future events
or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230503005864/en/
Media Kevin Giordano kgiordano@rocketpharma.com
Investors Brooks Rahmer investors@rocketpharma.com
Rocket Pharmaceuticals (NASDAQ:RCKT)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Rocket Pharmaceuticals (NASDAQ:RCKT)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024